Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of duchenne muscular dystrophy

Human Molecular Genetics

Volumn 23, Issue 6, 2014, Pages 1492-1505

  Hindi, Sajedah M ^a   Sato, Shuichi ^a   Choi, Yongwon ^b   Kumar, Ashok ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; AUTOPHAGY; CELL PROLIFERATION; CYTOKINES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; MICE; MICE, INBRED MDX; MICE, KNOCKOUT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; NF-KAPPA B; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84894371580     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt536     Document Type: Article

References (66)

1. Koenig, M., Hoffman, E.P., Bertelson, C.J., Monaco, A.P., Feener, C. and Kunkel, L.M. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50, 509-517.
2. Hoffman, E.P., Brown, R.H. Jr and Kunkel, L.M. (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 51, 919-928.
3. Rando, T.A. (2001) The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve, 24, 1575-1594.
4. Petrof, B.J., Shrager, J.B., Stedman, H.H., Kelly, A.M. and Sweeney, H.L. (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA, 90, 3710-3714.
5. Engvall, E. and Wewer, U.M. (2003) The newfrontier in muscular dystrophy research: booster genes. FASEB J., 17, 1579-1584.
6. Khurana, T.S. and Davies, K.E. (2003) Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug. Discov., 2, 379-390.
7. Chakkalakal, J.V., Thompson, J., Parks, R.J. and Jasmin, B.J. (2005) Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J., 19, 880-891.
8. Spencer, M.J. and Tidball, J.G. (2001) Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul. Disord., 11, 556-564.
9. Acharyya, S., Villalta, S.A., Bakkar, N., Bupha-Intr, T., Janssen, P.M., Carathers, M., Li, Z.W., Beg, A.A., Ghosh, S., Sahenk, Z. et al. (2007) Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest., 117, 889-901.
10. Bhatnagar, S. and Kumar, A. (2010) Therapeutic targeting of signaling pathways in muscular dystrophy. J. Mol. Med., 88, 155-166.
11. Dogra, C., Changotra, H., Wergedal, J.E. and Kumar, A. (2006) Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J. Cell Physiol., 208, 575-585.
12. Dogra, C., Srivastava, D.S. and Kumar, A. (2008) Protein-DNAarray-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice. Mol. Cell Biochem., 312, 17-24.
13. Kumar, A. and Boriek, A.M. (2003) Mechanical stress activates the nuclear factor-kappaBpathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J., 17, 386-396.
14. Kumar, A., Khandelwal, N., Malya, R., Reid, M.B. and Boriek, A.M. (2004) Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J., 18, 102-113.
15. Chung, J.Y., Park, Y.C., Ye, H. andWu, H. (2002) AllTRAFsare not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J. Cell Sci., 115, 679-688.
16. Zapata, J.M., Lefebvre, S. and Reed, J.C. (2007) Targeting TRAfs for therapeutic intervention. Adv. Exp. Med. Biol., 597, 188-201.
17. Bradley, J.R. and Pober, J.S. (2001) Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene, 20, 6482-6491.
18. Chung, J.Y., Lu, M., Yin, Q., Lin, S.C. andWu, H. (2007) Molecular basis for the unique specificity of TRAF6. Adv. Exp. Med. Biol., 597, 122-130.
19. Moscat, J., Diaz-Meco, M.T. and Wooten, M.W. (2007) Signal integration and diversification through the p62 scaffold protein. Trends Biochem. Sci., 32, 95-100.
20. Chen, Z.J. (2005) Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol., 7, 758-765.
21. Skaug, B., Jiang, X. and Chen, Z.J. (2009) The role of ubiquitin in NF-kappaB regulatory pathways. Annu. Rev. Biochem., 78, 769-796.
22. Yang, W.L., Wang, J., Chan, C.H., Lee, S.W., Campos, A.D., Lamothe, B., Hur, L., Grabiner, B.C., Lin, X., Darnay, B.G. et al. (2009) The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science, 325, 1134-1138.
23. Nakamura, K., Kimple, A.J., Siderovski, D.P. and Johnson, G.L. (2010) PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kappaB activation. J. Biol. Chem., 285, 2077-2089.
24. Seibenhener, M.L., Babu, J.R., Geetha, T., Wong, H.C., Krishna, N.R. and Wooten, M.W. (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol. Cell Biol., 24, 8055-8068.
25. Wooten, M.W., Geetha, T., Seibenhener, M.L., Babu, J.R., Diaz-Meco, M.T. and Moscat, J. (2005) The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J. Biol. Chem., 280, 35625-35629.
26. Shi, C.S. and Kehrl, J.H. (2010) TRAF6 And A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci. Signal, 3, ra42.
27. Hindi, S.M., Paul, P.K., Dahiya, S., Mishra, V., Bhatnagar, S., Kuang, S., Choi, Y. and Kumar, A. (2012) Reciprocal interaction between TRAF6 and notch signaling regulates adult myofiber regeneration upon injury. Mol. Cell Biol., 32, 4833-4845.
28. Paul, P.K., Bhatnagar, S., Mishra, V., Srivastava, S., Darnay, B.G., Choi, Y. and Kumar, A. (2012) The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms. Mol. Cell Biol., 32, 1248-1259.
29. Paul, P.K., Gupta, S.K., Bhatnagar, S., Panguluri, S.K., Darnay, B.G., Choi, Y. and Kumar, A. (2010) Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol., 191, 1395-1411.
30. Sandri, M. (2010)Autophagyinskeletalmuscle. FEBSLett., 584, 1411-1416.
31. Mammucari, C., Milan, G., Romanello, V., Masiero, E., Rudolf, R., Del Piccolo, P., Burden, S.J., Di Lisi, R., Sandri, C., Zhao, J. et al. (2007) Foxo3 controls autophagy in skeletal muscle in vivo. Cell Metab., 6, 458-471.
32. Masiero, E., Agatea, L., Mammucari, C., Blaauw, B., Loro, E., Komatsu, M., Metzger, D., Reggiani, C., Schiaffino, S. and Sandri, M.(2009) Autophagy is required to maintain muscle mass. Cell Metab., 10, 507-515.
33. Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S.H. and Goldberg, A.L. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell, 117, 399-412.
34. Zhao, J., Brault, J.J., Schild, A., Cao, P., Sandri, M., Schiaffino, S., Lecker, S.H. and Goldberg, A.L. (2007) Foxo3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab., 6, 472-483.
35. Depalma, C., Morisi, F., Cheli, S., Pambianco, S., Cappello, V., Vezzoli, M., Rovere-Querini, P., Moggio, M., Ripolone, M., Francolini, M. et al. (2012) Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis., 3, e418.
36. Bulfield, G., Siller, W.G., Wight, P.A. and Moore, K.J. (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. USA, 81, 1189-1192.
37. Stedman, H.H., Sweeney, H.L., Shrager, J.B., Maguire, H.C., Panettieri, R.A., Petrof, B., Narusawa, M., Leferovich, J.M., Sladky, J.T. and Kelly, A.M. (1991) The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature, 352, 536-539.
38. Dangain, J. and Vrbova, G. (1984) Muscle development inmdxmutant mice. Muscle Nerve, 7, 700-704.
39. Dimario, J.X., Uzman, A. and Strohman, R.C. (1991) Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. Dev. Biol., 148, 314-321.
40. Lamothe, B., Besse, A., Campos, A.D., Webster, W.K., Wu, H. and Darnay, B.G. (2007) Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J. Biol. Chem., 282, 4102-4112.
41. Lamothe, B., Webster, W.K., Gopinathan, A., Besse, A., Campos, A.D. and Darnay, B.G. (2007) TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem. Biophys. Res. Commun., 359, 1044-1049.
42. Tidball, J.G. and Wehling-Henricks, M.(2005)Damageandinflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr. Opin. Rheumatol., 17, 707-713.
43. Kumar, A., Takada, Y., Boriek, A.M. and Aggarwal, B.B. (2004) Nuclear factor-kappaB: its role in health and disease. J. Mol. Med., 82, 434-448.
44. Li, H., Malhotra, S. and Kumar, A. (2008) Nuclear factor-kappa B signaling in skeletal muscle atrophy. J. Mol. Med., 86, 1113-1126.
45. Peterson, J.M., Bakkar, N. and Guttridge, D.C. (2011) NF-kappaB signaling in skeletal muscle health and disease. Curr. Top. Dev. Biol., 96, 85-119.
46. Lu, A., Proto, J.D., Guo, L., Tang, Y., Lavasani, M., Tilstra, J.S., Niedernhofer, L.J., Wang, B., Guttridge, D.C., Robbins, P.D. et al. (2012) NF-kappaB negatively impacts the myogenic potential of muscle-derived stem cells. Mol. Ther., 20, 661-668.
47. Kuang, S., Charge, S.B., Seale, P., Huh, M. and Rudnicki, M.A. (2006) Distinct roles for Pax7 and Pax3 in adult regenerative myogenesis. J. Cell Biol., 172, 103-113.
48. Kuang, S., Gillespie, M.A. and Rudnicki, M.A. (2008) Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell, 2, 22-31.
49. Kuang, S., Kuroda, K., Le Grand, F. and Rudnicki, M.A. (2007)Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell, 129, 999-1010.
50. Mann, C.J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A.L. and Munoz-Canoves, P. (2011) Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle, 1, 21.
51. Bernasconi, P., Torchiana, E., Confalonieri, P., Brugnoni, R., Barresi, R., Mora, M., Cornelio, F., Morandi, L. and Mantegazza, R. (1995) Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J. Clin. Invest., 96, 1137-1144.
52. Peter, A.K. and Crosbie, R.H. (2006) Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. Exp. Cell Res., 312, 2580-2591.
53. Shin, J., Tajrishi, M.M., Ogura, Y. and Kumar, A. (2013) Wasting mechanisms in muscular dystrophy. Int. J. Biochem. Cell Biol., 45, 2266-2279.
54. Charge, S.B. and Rudnicki, M.A. (2004) Cellular and molecular regulation of muscle regeneration. Physiol. Rev., 84, 209-238.
55. Kuang, S. and Rudnicki, M.A. (2008) The emerging biology of satellite cells and their therapeutic potential. Trends Mol. Med., 14, 82-91.
56. Langen, R.C., Schols, A.M., Kelders, M.C., Wouters, E.F. and Janssen-Heininger, Y.M. (2001) Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J., 15, 1169-1180.
57. Langen, R.C., Van Der Velden, J.L., Schols, A.M., Kelders, M.C., Wouters, E.F. and Janssen-Heininger, Y.M. (2004) Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J., 18, 227-237.
58. Guttridge, D.C., Mayo, M.W., Madrid, L.V., Wang, C.Y. and Baldwin, A.S. Jr (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science, 289, 2363-2366.
59. Peterson, J.M. and Guttridge, D.C. (2008) Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. Int. Rev. Immunol., 27, 375-387.
60. Dogra, C., Changotra, H., Mohan, S. and Kumar, A. (2006) Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J. Biol. Chem., 281, 10327-10336.
61. Bonaldo, P. and Sandri, M. (2013) Cellular and molecular mechanisms of muscle atrophy. Dis. Model Mech., 6, 25-39.
62. Pauly, M., Daussin, F., Burelle, Y., Li, T., Godin, R., Fauconnier, J., Koechlin-Ramonatxo, C., Hugon, G., Lacampagne, A., Coisy-Quivy, M. et al. (2012) AMPK Activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm. Am. J. Pathol., 181, 583-592.
63. Manning, B.D. and Cantley, L.C. (2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261-1274.
64. Kim, M.H., Kay, D.I., Rudra, R.T., Chen, B.M., Hsu, N., Izumiya, Y., Martinez, L., Spencer, M.J., Walsh, K., Grinnell, A.D. et al. (2011) Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice. Hum. Mol. Genet., 20, 1324-1338.
65. Yamauchi, J., Kumar, A., Duarte, L., Mehuron, T. and Girgenrath, M.(2013) Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A. Hum. Mol. Genet., 22, 4306-4317.
66. Srivastava, A.K., Qin, X., Wedhas, N., Arnush, M., Linkhart, T.A., Chadwick, R.B. and Kumar, A. (2007) Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway. J. Biol. Chem., 282, 35113-35124.